Xilio Development, Inc.
Waltham, MA, US· latest recorded location
Xilio Development, Inc. is named on 9 US grants and 25 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 9
- Published applications
- 25
- Inventors
- 17
- Granted in 2026 so far
- 1
- Most recent grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2021 | 1 | 1 |
| 2022 | 0 | 6 |
| 2023 | 3 | 9 |
| 2024 | 1 | 1 |
| 2025 | 3 | 4 |
| 2026 | 1 | 4 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 34 documents
Recent patents
- Masked IL-2 cytokines and methods of use thereof23 Jun 2026US 12,662,520 B2
- Anti-CTLA4 antibodies and methods of use thereof7 Oct 2025US 12,435,142 B2
- Activatable masked anti-CTLA4 binding proteins12 Aug 2025US 12,384,845 B2
- Tumor-specific cleavable linkers22 Apr 2025US 12,280,120 B2
- Masked IL-2-Fc fusion polypeptides9 Jan 2024US 11,866,476 B2
- Anti-ctla4 antibodies and methods of use thereof7 May 2026US 2026/0125475 A1
- Tumor-specific cleavable linkers30 Apr 2026US 2026/0115302 A1
- Masked cytokine polypeptides30 Apr 2026US 2026/0116940 A1
- Masked il-2 cytokines and methods of use thereof8 Jan 2026US 2026/0008831 A1
- Activatable masked anti-ctla4 binding proteins18 Sep 2025US 2025/0289889 A1
Most cited
By later US patents